HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 292/1/L178    most recent 00205.2006v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by Höhne, C. Articles by Swenson, E. R. Search for Related Content PubMed PubMed Citation Articles by Höhne, C. Articles by Swenson, E. R.

Pulmonary vasodilation by acetazolamide during hypoxia is unrelated to carbonic anhydrase inhibition

¹Department of Anesthesiology and Intensive Care Medicine, Campus Virchow-Klinikum and Campus Charité Mitte, Charité-Universitaetsmedizin, Berlin, Germany; and ²Department of Medicine, University of Washington, Seattle, Washington

Submitted 7 June 2006 ; accepted in final form 17 August 2006

Acute hypoxic pulmonary vasoconstriction can be inhibited by high doses of the carbonic anhydrase inhibitor acetazolamide. This study aimed to determine whether acetazolamide is effective at dosing relevant to human use at high altitude and to investigate whether its efficacy against hypoxic pulmonary vasoconstriction is dependent on carbonic anhydrase inhibition by testing other potent heterocyclic sulfonamide carbonic anhydrase inhibitors. Six conscious dogs were studied in five protocols: 1) controls, 2) low-dose intravenous acetazolamide (2 mg·kg^–1·h^–1), 3) oral acetazolamide (5 mg/kg), 4) benzolamide, a membrane-impermeant inhibitor, and 5) ethoxzolamide, a membrane-permeant inhibitor. In all protocols, unanesthetized dogs breathed spontaneously during the first hour (normoxia) and then breathed 9–10% O₂ for the next 2 h. Arterial oxygen tension ranged between 35 and 39 mmHg during hypoxia in all protocols. In controls, mean pulmonary artery pressure increased by 8 mmHg and pulmonary vascular resistance by 200 dyn·s·cm^–5 (P <0.05). With intravenous acetazolamide, mean pulmonary artery pressure and pulmonary vascular resistance remained unchanged during hypoxia. With oral acetazolamide, mean pulmonary artery pressure increased by 5 mmHg (P < 0.05), but pulmonary vascular resistance did not change during hypoxia. With benzolamide and ethoxzolamide, mean pulmonary artery pressure increased by 6–7 mmHg and pulmonary vascular resistance by 150–200 dyn·s·cm^–5 during hypoxia (P < 0.05). Low-dose acetazolamide is effective against acute hypoxic pulmonary vasoconstriction in vivo. The lack of effect with two other potent carbonic anhydrase inhibitors suggests that carbonic anhydrase is not involved in the mediation of hypoxic pulmonary vasoconstriction and that acetazolamide acts on a different receptor or channel.

high altitude; benzolamide; ethoxzolamide; hypoxic pulmonary vasoconstriction

This article has been cited by other articles:

				H. F. Kiwull-Schone, Y. Li, P. J. Kiwull, and L. J. Teppema Methazolamide does not impair respiratory work performance in anesthetized rabbits Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2009; 297(3): R648 - R654. [Abstract] [Full Text] [PDF]

				M. S. Torring, K. Holmgaard, A. Hessellund, C. Aalkjaer, and T. Bek The Vasodilating Effect of Acetazolamide and Dorzolamide Involves Mechanisms Other Than Carbonic Anhydrase Inhibition Invest. Ophthalmol. Vis. Sci., January 1, 2009; 50(1): 345 - 351. [Abstract] [Full Text] [PDF]

				J.-P. Richalet, M. Rivera-Ch, M. Maignan, C. Privat, I. Pham, J.-L. Macarlupu, O. Petitjean, and F. Leon-Velarde Acetazolamide for Monge's Disease: Efficiency and Tolerance of 6-Month Treatment Am. J. Respir. Crit. Care Med., June 15, 2008; 177(12): 1370 - 1376. [Abstract] [Full Text] [PDF]

				A. M. Luks and E. R. Swenson Medication and Dosage Considerations in the Prophylaxis and Treatment of High-Altitude Illness Chest, March 1, 2008; 133(3): 744 - 755. [Abstract] [Full Text] [PDF]

				V. Faoro, S. Huez, S. Giltaire, A. Pavelescu, A. van Osta, J.-J. Moraine, H. Guenard, J.-B. Martinot, and R. Naeije Effects of acetazolamide on aerobic exercise capacity and pulmonary hemodynamics at high altitudes J Appl Physiol, October 1, 2007; 103(4): 1161 - 1165. [Abstract] [Full Text] [PDF]

				E. R. Swenson and L. J. Teppema Prevention of acute mountain sickness by acetazolamide: as yet an unfinished story J Appl Physiol, April 1, 2007; 102(4): 1305 - 1307. [Full Text] [PDF]